1. Home
  2. BRUN vs CRVS Comparison

BRUN vs CRVS Comparison

Compare BRUN & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Boost Run Inc. Class A Common Stock

BRUN

Boost Run Inc. Class A Common Stock

N/A

Current Price

$16.62

Market Cap

1.4B

Sector

Technology

ML Signal

N/A

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

HOLD

Current Price

$12.96

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRUN
CRVS
Founded
N/A
2014
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.3B
IPO Year
2026
2016

Fundamental Metrics

Financial Performance
Metric
BRUN
CRVS
Price
$16.62
$12.96
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$30.17
AVG Volume (30 Days)
2.4M
661.6K
Earning Date
N/A
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
48.04
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.56
$5.64
52 Week High
$40.46
$26.95

Technical Indicators

Market Signals
Indicator
BRUN
CRVS
Relative Strength Index (RSI) 40.40 36.72
Support Level $16.34 $12.76
Resistance Level $20.91 $14.00
Average True Range (ATR) 1.68 0.56
MACD 0.12 -0.16
Stochastic Oscillator 14.81 10.78

Price Performance

Historical Comparison
BRUN
CRVS

About BRUN Boost Run Inc. Class A Common Stock

Boost Run Inc is an NVIDIA Cloud Provider. Its platform provides GPU compute, CPU nodes, managed Kubernetes orchestration, and shared storage through an intuitive management console and a robust API layer, enabling organizations to provision and scale resources across thousands of nodes in minutes. Enterprises rely on Boost Run to power their main demanding AI workloads with the performance, security, and reliability their operations require. The group maintains SOC 2 Type II, HIPAA, ISO 27001, and ISO 27701 certifications at the operator level, and partners with data center facilities that uphold equivalent security and compliance standards.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Share on Social Networks: